Abstract:Radiation recall reaction (RRR) refers to the inflammatory reaction in a previously irradiated area after exposure to a certain systemic agent. It most often affects the skin, but there are also reports of other organs and systems, such as the lung, gastrointestinal tract, muscle, and central nervous system being affected.1Burris 3rd, H.A. Hurtig J. Radiation recall with anticancer agents.Oncologist. 2010; 15: 1227-1237Crossref PubMed Scopus (166) Google Scholar It is reported that several chemotherapy and target therapy drugs can cause RRR. With the emergence and frequent use of immune checkpoint inhibitors (ICIs), reports of immunotherapy-induced RRR began to appear in the literature.2McGovern K. Ghaly M. Esposito M. Barnaby K. Seetharamu N. Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review.Future Sci OA. 2019; 5FSO378Crossref PubMed Scopus (13) Google Scholar Here, we report a case of concomitant radiation recall dermatitis (RRD) and radiation recall pneumonitis (RRP) induced by pembrolizumab, a humanized antiprogrammed cell death protein-1 monoclonal antibody, in a patient with SCLC. A 52-year-old Chinese man was diagnosed as having extensive-stage SCLC owing to a metastatic lesion in the left adrenal gland. After etoposide and cisplatin regimen chemotherapy, the patient received sequential radiotherapy. The residual primary lung lesion and mediastinal and supraclavicular enlarged lymph nodes were irradiated with a total dose of 50 Gy within 5 weeks. The mean lung dose was 13.4 Gy. The volume of the lung that received 20 Gy (V20) was 25%. Six months after radiotherapy, the enlarged primary lung lesion was found on a chest computed tomography (CT) scan of the patient. Through a multidisciplinary team meeting, a combination of immunotherapy and chemotherapy was recommended to manage the relapse of the lung lesion. Nevertheless, 3 days after the start of 200 mg pembrolizumab, the patient developed a confluent erythematous rash with superficial edema on his skin limited to the previously irradiated supraclavicular area (Fig. 1). At the same time, the patient also developed dyspnea, nonproductive cough, and low-grade fever. A chest CT scan revealed a new, patchy consolidation with confluent ground-glass opacity located in the previously irradiated area (Fig. 2). Bacterial or fungal infection was ruled out, and the patient was diagnosed as having RRD and RRP induced by pembrolizumab. Prednisolone was immediately started and tapered for more than 6 weeks. The symptoms of RRD and RRP reduced rapidly after the treatment. Results of a repeated chest CT scan revealed that RRP was significantly improved.Figure 2The radiation field and representative images of a 52-year-old male patient with SCLC obtained during radiation recall pneumonia induced by pembrolizumab and 1 month after prednisolone treatment.View Large Image Figure ViewerDownload Hi-res image Download (PPT) RRR is a special type of inflammatory reaction that occurs in a previously irradiated field. The incidence of RRR triggered by chemotherapeutic drugs is 8.8%.1Burris 3rd, H.A. Hurtig J. Radiation recall with anticancer agents.Oncologist. 2010; 15: 1227-1237Crossref PubMed Scopus (166) Google Scholar The incidence of RRP caused by targeted therapy is 4.4%.3Chiang C.L. Chen Y.W. Wu M.H. Huang H.C. Tsai C.M. Chiu C.H. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer.J Chin Med Assoc. 2016; 79: 248-255Crossref PubMed Scopus (17) Google Scholar The incidence of RRR induced by ICI is unknown owing to the rarity of the disease. To date, cases of ICI-induced RRR have been reported most frequently in treatments that involved nivolumab. RRD, RRP, and myelitis caused by pembrolizumab also appear in the literature. To our knowledge, this is the first case of pembrolizumab-induced concomitant RRD and RRP in a patient with SCLC. In fact, cutaneous and pulmonary toxicities are common immune-related adverse events associated with ICIs. Higher rates are found with combination therapy than monotherapy.4Naidoo J. Page D.B. Li B.T. et al.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Ann Oncol. 2015; 26: 2375-2391Abstract Full Text Full Text PDF PubMed Scopus (715) Google Scholar For these reasons, the diagnosis of RRR is full of challenges. Usually, the diagnosis of RRR depends on the sequence of use of radiotherapy, drugs of concern, and shape of the skin lesion or the chest radiologic changes in a patient. Although the mechanism of RRR induced by pembrolizumab is not clear, its clinical manifestation may be different from that of RRR induced by chemotherapy or target therapy agents. By reviewing current case reports, it is not difficult to find that an important feature of RRR caused by ICI is that the time interval between the beginning of ICI and onset of RRR was shorter than that of RRR caused by chemotherapy or targeted therapy drugs.5Billena C. Padia S. O’Brien B. Knoble J. Gokhale A. Rajagopalan M. Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: a case report.Immunotherapy. 2020; 12: 123-130Crossref PubMed Scopus (2) Google Scholar Therefore, radiation recall toxicity caused by ICI should be closely monitored to prevent further expansion of the lesions and to provide appropriate treatment in the early stage. The treatment of RRR depends on the severity of symptoms. The procedure includes observation, symptom management, withdrawal of the precipitating drug, and application of systematic steroids.1Burris 3rd, H.A. Hurtig J. Radiation recall with anticancer agents.Oncologist. 2010; 15: 1227-1237Crossref PubMed Scopus (166) Google Scholar Fortunately, ICI-induced RRR can be successfully controlled by steroids. Nevertheless, the rechallenge of ICI involves careful assessment of its risks and benefits. Pembrolizumab is becoming an increasingly popular ICI in the management of cancer. It is important to pay attention to occasional radiation recalls, including RRD and RRP.

Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes

Radiation recall with vinorelbine and cisplatin.

Gemcitabine-Induced Radiation Recall Phenomenon in Cervical Cancer: A Case Report

Radiation recall dermatitis in HER 2 positive breast cancer patients triggered by trastuzumab: A rare case report and review of literature

Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review

Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis

Concomitant Radiation Recall Dermatitis and Radiation Recall Pneumonitis Induced by Pembrolizumab

Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab Treatment

Radiation-Recall Skin Disorders Associated With the Use of Antineoplastic Drugs

Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization

Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: a case report

DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY

Radiation-induced tumors in children irradiated for brain tumor: a longitudinal study

Symptom-Focused Approach

Radiation-Related New Primary Solid Cancers in the Childhood Cancer Survivor Study: Comparative Radiation Dose Response and Modification of Treatment Effects

Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature

Risk-Stratified Radiotherapy in Pediatric Cancer

Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study

Wee1 Kinase Inhibitor Adavosertib with Radiation in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Phase I Consortium Study.

Late‐onset lymphopenia during radiation is associated with an increased risk of tumor recurrence in newly diagnosed pediatric medulloblastoma

Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation